Melanie Sloan1, Caroline Gordon2, Elliott Lever3, Rupert Harwood4, Michael A Bosley4, Mark Pilling1, James Brimicombe1, Felix Naughton5, Moira Blane4, Chanpreet Walia6, David D'Cruz7. 1. Department of Public Health and Primary Care, University of Cambridge School of Clinical Medicine, Cambridge. 2. Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Science, University of Birmingham, Birmingham. 3. Rheumatology Department, Northwick Park Hospital, London. 4. Patient and Public Involvement in Lupus Research Group, Institute of Public Health, University of Cambridge, Cambridge. 5. Behavioural and Implementation Science Group, School of Health Sciences, University of East Anglia, Norwich. 6. LUPUS UK, St James House, Romford. 7. The Louise Coote Lupus unit, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Abstract
OBJECTIVE: The shielding guidance in the UK for the clinically extremely vulnerable (CEV) commenced on 23 March 2020 in response to the coronavirus disease 2019 (COVID-19) pandemic. The purpose of this study was to explore the impact of the pandemic and shielding on patients with lupus and related systemic autoimmune rheumatic diseases (SARDs). METHODS: This was a mixed-methods cohort study (n = 111) including pre-lockdown baseline surveys (March 2020), follow-up surveys (June 2020) and in-depth interviews during July 2020 (n = 25). RESULTS: Most participants had a high level of anxiety regarding their mortality risk from COVID-19 and supported the concept of shielding. Shielding allocations and communications were perceived as inconsistently applied and delivered. More than half of those not classified as CEV reported feeling abandoned, at increased risk and with no support. Shielding communications increased feelings of being 'cared about', but also increased fear, and the 'vulnerable' labelling was perceived by some to damage social and self-identity. More than 80% of those classified as CEV stated that the classification and subsequent communications had changed their social-mixing behaviour. Despite many negative impacts of COVID-19 and shielding/lockdown being identified, including isolation, fear and reduced medical care, the quantitative data during the pandemic showed increases in most measures of wellbeing (which was low at both time points) from pre-lockdown, including reductions in the impact of fatigue and pain (P-values < 0.001). CONCLUSION: Shielding classifications and communications were, in general, viewed positively, although they were perceived as inconsistently delivered and anxiety-provoking by some participants. More frequent positively framed communication and wellbeing support could benefit all SARD patients. Slower-paced lockdown lifestyles might confer health/wellbeing benefits for some people with chronic diseases.
OBJECTIVE: The shielding guidance in the UK for the clinically extremely vulnerable (CEV) commenced on 23 March 2020 in response to the coronavirus disease 2019 (COVID-19) pandemic. The purpose of this study was to explore the impact of the pandemic and shielding on patients with lupus and related systemic autoimmune rheumatic diseases (SARDs). METHODS: This was a mixed-methods cohort study (n = 111) including pre-lockdown baseline surveys (March 2020), follow-up surveys (June 2020) and in-depth interviews during July 2020 (n = 25). RESULTS: Most participants had a high level of anxiety regarding their mortality risk from COVID-19 and supported the concept of shielding. Shielding allocations and communications were perceived as inconsistently applied and delivered. More than half of those not classified as CEV reported feeling abandoned, at increased risk and with no support. Shielding communications increased feelings of being 'cared about', but also increased fear, and the 'vulnerable' labelling was perceived by some to damage social and self-identity. More than 80% of those classified as CEV stated that the classification and subsequent communications had changed their social-mixing behaviour. Despite many negative impacts of COVID-19 and shielding/lockdown being identified, including isolation, fear and reduced medical care, the quantitative data during the pandemic showed increases in most measures of wellbeing (which was low at both time points) from pre-lockdown, including reductions in the impact of fatigue and pain (P-values < 0.001). CONCLUSION: Shielding classifications and communications were, in general, viewed positively, although they were perceived as inconsistently delivered and anxiety-provoking by some participants. More frequent positively framed communication and wellbeing support could benefit all SARD patients. Slower-paced lockdown lifestyles might confer health/wellbeing benefits for some people with chronic diseases.
Authors: Ruth Tennant; Louise Hiller; Ruth Fishwick; Stephen Platt; Stephen Joseph; Scott Weich; Jane Parkinson; Jenny Secker; Sarah Stewart-Brown Journal: Health Qual Life Outcomes Date: 2007-11-27 Impact factor: 3.186
Authors: Emily A Holmes; Rory C O'Connor; V Hugh Perry; Irene Tracey; Simon Wessely; Louise Arseneault; Clive Ballard; Helen Christensen; Roxane Cohen Silver; Ian Everall; Tamsin Ford; Ann John; Thomas Kabir; Kate King; Ira Madan; Susan Michie; Andrew K Przybylski; Roz Shafran; Angela Sweeney; Carol M Worthman; Lucy Yardley; Katherine Cowan; Claire Cope; Matthew Hotopf; Ed Bullmore Journal: Lancet Psychiatry Date: 2020-04-15 Impact factor: 27.083
Authors: Lena M Hassen; Rana A Albarrak; Reem A Albahlal; Dimah K Alsaqabi; Ikhlass M Hassen; Maha H Daghestani; Eman M Alqurtas; Abdulaziz T Alkhalaf; Mohammed K Bedaiwi; Mohammed A Omair; Ibrahim A Almaghlouth Journal: Qual Life Res Date: 2022-07-20 Impact factor: 3.440
Authors: Siobhan C McKay; Hanns Lembach; Angus Hann; Kelvin Okoth; Joy Anderton; Krishnarajah Nirantharakumar; Laura Magill; Barbara Torlinska; Matthew Armstrong; Jorge Mascaro; Nicholas Inston; Thomas Pinkney; Aaron Ranasinghe; Richard Borrows; James Ferguson; John Isaac; Melanie Calvert; M Thamara P R Perera; Hermien Hartog Journal: Transpl Int Date: 2021-09-16 Impact factor: 3.842
Authors: Ho So; Evelyn Chow; Isaac T Cheng; Sze-Lok Lau; Tena K Li; Cheuk-Chun Szeto; Lai-Shan Tam Journal: Lupus Date: 2022-03-07 Impact factor: 2.911
Authors: Sarah Ryan; Paul Campbell; Zoe Paskins; Samantha Hider; Fay Manning; Katrina Rule; Michael Brooks; Andrew Hassell Journal: BMJ Open Date: 2022-07-26 Impact factor: 3.006
Authors: Christian Ammitzbøll; Marianne Kragh Thomsen; Jakob Bøgh Andersen; Lars Erik Bartels; Marie-Louise From Hermansen; Anders Dahl Johannsen; Clara Elbæk Mistegaard; Susan Mikkelsen; Signe Risbøl Vils; Christian Erikstrup; Ellen-Margrethe Hauge; Anne Troldborg Journal: Mod Rheumatol Date: 2022-07-21 Impact factor: 2.862
Authors: Duvuru Geetha; Andreas Kronbichler; Megan Rutter; Divya Bajpai; Steven Menez; Annemarie Weissenbacher; Shuchi Anand; Eugene Lin; Nicholas Carlson; Stephen Sozio; Kevin Fowler; Ray Bignall; Kathryn Ducharlet; Elliot K Tannor; Eranga Wijewickrama; Muhammad I A Hafidz; Vladimir Tesar; Robert Hoover; Deidra Crews; Charles Varnell; Lara Danziger-Isakov; Vivekanand Jha; Sumit Mohan; Chirag Parikh; Valerie Luyckx Journal: Nat Rev Nephrol Date: 2022-08-24 Impact factor: 42.439